AbbVie
ABBV
ABBV
3,155 hedge funds and large institutions have $255B invested in AbbVie in 2022 Q4 according to their latest regulatory filings, with 362 funds opening new positions, 1,187 increasing their positions, 1,258 reducing their positions, and 101 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
0.19% less ownership
Funds ownership: 69.96% → 69.77% (-0.19%)
4% less call options, than puts
Call options by funds: $2.99B | Put options by funds: $3.13B
6% less repeat investments, than reductions
Existing positions increased: 1,187 | Existing positions reduced: 1,258
Holders
3,155
Holding in Top 10
346
Calls
$2.99B
Puts
$3.13B
Top Buyers
| 1 | +$2.25B | |
| 2 | +$928M | |
| 3 | +$773M | |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$530M |
| 5 |
JPMorgan Chase & Co
New York
|
+$393M |
Top Sellers
| 1 | -$2.73B | |
| 2 | -$662M | |
| 3 | -$432M | |
| 4 |
CIAS
CFS Investment Advisory Services
Totowa,
New Jersey
|
-$399M |
| 5 |
Nuveen Asset Management
Chicago,
Illinois
|
-$196M |